Form 4: Legend Biotech CEO Sells Shares for Tax Obligations

Legend Biotech Corp's CEO, Huang Ying, sold 9,936 ordinary shares to cover tax obligations related to restricted share unit vesting.

Summary

• Huang Ying, Chief Executive Officer and Director of Legend Biotech Corp, reported a transaction on March 25, 2026.
• The transaction involved the sale of 9,936 ordinary shares.
• The shares were sold at a weighted average price of $8.77 per ordinary share.
• The sale was executed to satisfy withholding tax obligations upon the vesting of restricted share units.
• Following this transaction, Huang Ying beneficially owns 247,438 ordinary shares directly.
• Ordinary shares of Legend Biotech Corp may be represented by American Depositary Shares (ADSs), with each ADS representing two ordinary shares.
• The reported price range for the sale was $17.26 to $17.82 per ADS, equivalent to $8.63 to $8.91 per ordinary share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. The transaction is a routine administrative event for tax purposes and does not reflect a change in the company's operational or financial performance.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that sales of shares by executives to cover tax liabilities upon the vesting of equity awards, such as restricted share units, are a common and routine administrative event in the industry. These transactions are typically not indicative of a change in management's confidence in the company's future prospects.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine tax-related sale by an executive, not indicative of a change in company fundamentals or executive sentiment.

Key Dates

Recommendation

The transaction is a routine sale by an executive to cover tax obligations upon the vesting of restricted share units and does not indicate a change in the company's fundamentals or the executive's long-term view. Therefore, it does not warrant a change in investment recommendation.

Keywords

Legend Biotech, LEGN, Form 4, Insider Transaction, Share Sale, CEO, Restricted Share Units, Tax Obligations